Ipsen Appoints Baxalta's Oncology Chief Meek CEO
Ipsen has appointed Baxalta's head of oncology David Meek as its new CEO, having formerly instigated a search in February. Baxalta's $32bn acquisition by Shire completed at the start of June.
You may also be interested in...
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.
Genome-editing specialist Precision BioSciences says Baxalta Inc.'s increasing commitment to, and expertise in, immuno-oncology made it the obvious choice for the Duke University spinout to partner with on developing a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed against multiple cancers.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.